Advertisement

Current Medical Science

, Volume 38, Issue 6, pp 1005–1011 | Cite as

Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China

  • Li-feng Chen
  • Guo-lin Yuan
  • Zhao-dong Zhong
  • Ping Zou
  • Deng-ju Li
  • Yin Bao
  • Hong-bo Ren
  • Li Meng
  • Wei-ming Li
Article
  • 1 Downloads

Summary

Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) and it could be used as a second-line treatment for patients with chronic myeloid leukemia (CML). Yinishu, a generic dasatinib made in China, was approved by the China Food and Drug Administration in 2013 and it costs much less than the patented dasatinib SPRYCEL. The present study aimed to examine the efficacy and safety of Yinishu as a second-line treatment for CML by comparing the baseline clinical characteristics, rates of adverse events and efficacy between Yinishu and SPRYCEL groups. The results showed that there were no significant differences in the rates of optimal response between Yinishu and SPRYCEL for patients who started second-line treatment because of treatment failure. For patients who started second-line treatment because of intolerance of first-line treatment, their levels of BCR-ABL1/ABL1 on the international scale (BCR-ABLIS) was maintained very low throughout the course of Yinishu treatment. Drug-related adverse events occurred with the same frequency in these two groups. It was confirmed that Yinishu was effective and safe as a secondline treatment for CML patients. Yinishu may be more suitable for patients who are economically unable to pay for the patented dasatinib SPRYCEL.

Key words

chronic myeloid leukemia generic dasatinib second-line treatment efficacy safety 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

We would like to thank all the enrolled patients and their families as well as the investigators from the 11 contributing centers.

References

  1. 1.
    Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood, 2009,114:1126Google Scholar
  2. 2.
    Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood, 2012,119(9):1981–1987CrossRefGoogle Scholar
  3. 3.
    Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2012,119(5):1123–1129CrossRefGoogle Scholar
  4. 4.
    Cortes JE, Saglio G, Baccarani M, et al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood, 2014,124:152Google Scholar
  5. 5.
    Brummendorf TH, Cortes JE, De Souza, et al. Bosutinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol, 2015,168(1):69–81CrossRefGoogle Scholar
  6. 6.
    Wang J, Shen ZX, Saglio G, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood, 2015,125(18):2771–2778CrossRefGoogle Scholar
  7. 7.
    Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol, 2003,21(11):2138–2146CrossRefGoogle Scholar
  8. 8.
    Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood, 2009,113(22):5401–5411CrossRefGoogle Scholar
  9. 9.
    Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood, 2011,117(14):3733–3736CrossRefGoogle Scholar
  10. 10.
    Abboud C, Berman E, Cohen A, et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood, 2013,121(22):4439–4442CrossRefGoogle Scholar
  11. 11.
    Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol, 2013,32(4):306–311CrossRefGoogle Scholar
  12. 12.
    Smith AG, Painter D, Howell DA, et al. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open, 2014,4(1):e004266CrossRefGoogle Scholar
  13. 13.
    Jiang Q, Zhao D, Jin J, et al. A prospective, multicentre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia. Zhonghua Xue Ye Xue Za Zhi (Chinese), 2015,36(8):651–655Google Scholar
  14. 14.
    Jiang CF, Luo F, Lin SS, et al. Treatment of domestic imatinib Mesylate on 36 patients with Ph positivechronic myeloid leukemia. J Clin Hematol (China), 2016,29(9):757–759Google Scholar
  15. 15.
    Lv JL, Chen YP, Xiao Q, et al. Curative effect and safety analysis of 47 patients with chronic myeloid leukemia after imatinib Mesylate treatment. J Clin Hematol (China), 2016,29(3):222–225Google Scholar
  16. 16.
    Kong J, Fu HX, Lai YH, et al. Dasatinib of china Tai-tianqing as second line treatment for chronic myelogenous leukemia in chronic phase. J Clin Hematol (Chinese), 2016,29(11):898–901Google Scholar
  17. 17.
    Min H, Kaifeng Y, Xiaoming L, et al. Clinical effect of imatinib, nero imatinib and dasatinib on chronic myeloid leukemia in chronic phase. Chin J Clin Pharmacol, 2016,32(6):511–513Google Scholar
  18. 18.
    Wang JX. The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2016 edition). Zhonghua Xue Ye Xue Za Zhi (Chinese), 2016,37(8):633–639Google Scholar
  19. 19.
    Tan PF, Tan H, Luo XD. A case of chronic myeloid leukemia treated with dasatinib. J Clin Hematol (Chinese), 2016,29(1):69–70Google Scholar
  20. 20.
    Ferdinand R, Mitchell SA, Batson S, et al. Treatments for chronic myeloid leukemia: a qualitative systematic review. J Blood Med, 2012,3:51–76Google Scholar
  21. 21.
    Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinibresistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol, 2008,26(19):3204–3212CrossRefGoogle Scholar

Copyright information

© Huazhong University of Science and Technology 2018

Authors and Affiliations

  • Li-feng Chen
    • 1
  • Guo-lin Yuan
    • 2
  • Zhao-dong Zhong
    • 1
  • Ping Zou
    • 1
  • Deng-ju Li
    • 3
  • Yin Bao
    • 4
  • Hong-bo Ren
    • 5
  • Li Meng
    • 3
  • Wei-ming Li
    • 1
  1. 1.Department of Hematology, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of HematologyXiangyang Central HospitalXiangyangChina
  3. 3.Department of Hematology, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  4. 4.Department of HematologyXiangyang No. 1 People’s HospitalXiangyangChina
  5. 5.Department of Hematologythe First People’s Hospital of JingzhouJingzhouChina

Personalised recommendations